Legend Biotech (LEGN) Stock Forecast, Price Target & Predictions
LEGN Stock Forecast
Legend Biotech stock forecast is as follows: an average price target of $78.78 (represents a 63.14% upside from LEGN’s last price of $48.29) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
LEGN Price Target
The average price target for Legend Biotech (LEGN) is $78.78 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $60.00. This represents a potential 63.14% upside from LEGN's last price of $48.29.
LEGN Analyst Ratings
According to 12 Wall Street analysts, Legend Biotech's rating consensus is 'Buy'. The analyst rating breakdown for LEGN stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 1 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Legend Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Edward Tenthoff | Piper Sandler | $90.00 | $42.00 | 114.29% | 86.37% |
| Jun 17, 2024 | Asthika Goonewardene | Truist Financial | $88.00 | $42.45 | 107.30% | 82.23% |
| May 23, 2024 | James Shin | Deutsche Bank | $60.00 | $40.04 | 49.85% | 24.25% |
| May 17, 2024 | Matthew Harrison | Morgan Stanley | $82.00 | $46.37 | 76.84% | 69.81% |
| May 14, 2024 | Leonid Timashev | RBC Capital | $86.00 | $42.97 | 100.14% | 78.09% |
| Apr 17, 2024 | George Farmer | Scotiabank | $65.00 | $50.12 | 29.69% | 34.60% |
| Apr 03, 2024 | Rick Bienkowski | Cantor Fitzgerald | $82.00 | $56.43 | 45.31% | 69.81% |
| Mar 14, 2024 | Kostas Biliouris | BMO Capital | $90.00 | $66.11 | 36.14% | 86.37% |
| Dec 06, 2022 | - | UBS | $66.00 | $50.99 | 29.44% | 36.67% |
The latest Legend Biotech stock forecast, released on Jun 17, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $90.00, which represents a 114.29% increase from the stock price at the time of the forecast ($42.00), and a 86.37% increase from LEGN last price ($48.29).
Legend Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $89.00 | $80.38 |
| Last Closing Price | $48.29 | $48.29 | $48.29 |
| Upside/Downside | -100.00% | 84.30% | 66.45% |
In the current month, the average price target of Legend Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Legend Biotech's last price of $48.29. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | Scotiabank | Buy | Buy | Hold |
| Aug 12, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Aug 12, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Jul 18, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Jul 15, 2024 | Scotiabank | Buy | Buy | Hold |
| Jul 15, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jun 21, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jun 21, 2024 | Scotiabank | Buy | Buy | Hold |
| Jun 21, 2024 | RBC Capital | Outperform | Outperform | Hold |
Legend Biotech's last stock rating was published by H.C. Wainwright on Aug 28, 2024. The company gave LEGN a "Buy" rating, the same as its previous rate.
Legend Biotech Financial Forecast
Legend Biotech Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $36.34M | $25.21M | - | $11.97M | $40.83M | $38.99M | $16.88M | $20.23M | $13.68M | $40.78M | $11.75M | $11.60M |
| Avg Forecast | $474.50M | $432.20M | $393.67M | $358.58M | $291.47M | $253.44M | $241.84M | $188.82M | $171.22M | $136.16M | $125.25M | $143.24M | $94.08M | $97.25M | $56.64M | $42.18M | $36.06M | $33.62M | $33.62M | $14.27M | $7.83M | $9.13M | $6.50M | $13.00M | $13.00M | $13.00M | $29.71M |
| High Forecast | $505.79M | $460.70M | $419.63M | $382.23M | $310.69M | $270.16M | $257.80M | $201.27M | $182.51M | $147.86M | $133.52M | $152.69M | $106.19M | $103.67M | $60.37M | $44.96M | $38.44M | $35.84M | $33.62M | $18.69M | $10.26M | $11.96M | $8.51M | $17.03M | $17.03M | $17.03M | $35.66M |
| Low Forecast | $448.14M | $408.19M | $371.80M | $338.66M | $275.28M | $239.37M | $228.41M | $178.33M | $161.71M | $123.87M | $118.30M | $135.29M | $81.55M | $91.85M | $53.49M | $39.83M | $34.06M | $31.75M | $33.62M | $9.06M | $4.97M | $5.80M | $4.12M | $8.25M | $8.25M | $8.25M | $23.77M |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 6 | 10 | 10 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 0.70% | - | 0.36% | 2.86% | 4.98% | 1.85% | 3.11% | 1.05% | 3.14% | 0.90% | 0.39% |
Legend Biotech's average Quarter revenue forecast for Jun 23 based on 6 analysts is $56.64M, with a low forecast of $53.49M, and a high forecast of $60.37M. LEGN's average Quarter revenue forecast represents a 55.87% increase compared to the company's last Quarter revenue of $36.34M (Mar 23).
Legend Biotech EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 6 | 10 | 10 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-126.86M | $317.86M | - | $-125.53M | $-71.07M | $-87.73M | $-124.54M | $-91.53M | $-80.86M | $-61.73M | $-66.96M | $-134.79M |
| Avg Forecast | $-474.50M | $-432.20M | $-393.67M | $-358.58M | $-291.47M | $-253.44M | $-241.84M | $-188.82M | $-171.22M | $-136.16M | $-125.25M | $-143.24M | $-94.08M | $-97.25M | $-56.64M | $-42.18M | $-36.06M | $-33.62M | $-33.62M | $-11.83M | $-6.50M | $-96.08M | $-88.58M | $-92.41M | $-10.78M | $-28.51M | $-345.26M |
| High Forecast | $-448.14M | $-408.19M | $-371.80M | $-338.66M | $-275.28M | $-239.37M | $-228.41M | $-178.33M | $-161.71M | $-123.87M | $-118.30M | $-135.29M | $-81.55M | $-91.85M | $-53.49M | $-39.83M | $-34.06M | $-31.75M | $-33.62M | $-7.51M | $-4.12M | $-76.86M | $-70.86M | $-73.93M | $-6.84M | $-22.81M | $-276.21M |
| Low Forecast | $-505.79M | $-460.70M | $-419.63M | $-382.23M | $-310.69M | $-270.16M | $-257.80M | $-201.27M | $-182.51M | $-147.86M | $-133.52M | $-152.69M | $-106.19M | $-103.67M | $-60.37M | $-44.96M | $-38.44M | $-35.84M | $-33.62M | $-15.50M | $-8.51M | $-115.29M | $-106.29M | $-110.90M | $-14.12M | $-34.22M | $-414.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.01% | -8.81% | - | 3.73% | 6.01% | 13.51% | 1.30% | 1.03% | 0.88% | 5.73% | 2.35% | 0.39% |
3 analysts predict LEGN's average Quarter EBITDA for Mar 23 to be $-42.18M, with a high of $-39.83M and a low of $-44.96M. This is -113.27% lower than Legend Biotech's previous annual EBITDA (Dec 22) of $317.86M.
Legend Biotech Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 6 | 10 | 10 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-112.10M | $319.93M | - | $-193.23M | $-42.08M | $-84.62M | $-121.25M | $-91.58M | $-82.21M | $-57.83M | $-66.55M | $-213.63M |
| Avg Forecast | $77.62M | $66.10M | $45.58M | $27.79M | $-10.59M | $-23.37M | $-23.74M | $-40.17M | $-55.91M | $-61.90M | $-52.49M | $-35.33M | $-64.93M | $-56.63M | $-65.91M | $-76.23M | $-69.95M | $-56.64M | $-56.46M | $-62.15M | $-75.57M | $-96.24M | $-88.63M | $-92.46M | $-55.76M | $-28.34M | $-345.49M |
| High Forecast | $84.28M | $71.77M | $49.49M | $30.17M | $-9.83M | $-21.69M | $-22.02M | $-37.27M | $-51.87M | $-46.96M | $-48.70M | $-32.78M | $-38.96M | $-52.54M | $-61.15M | $-70.72M | $-64.90M | $-52.55M | $-56.46M | $-32.63M | $-39.67M | $-76.99M | $-70.90M | $-73.96M | $-29.27M | $-22.67M | $-276.39M |
| Low Forecast | $72.02M | $61.33M | $42.29M | $25.79M | $-11.50M | $-25.38M | $-25.77M | $-43.62M | $-60.70M | $-81.11M | $-56.99M | $-38.36M | $-79.77M | $-61.48M | $-71.56M | $-82.76M | $-75.95M | $-61.50M | $-56.46M | $-87.17M | $-105.99M | $-115.48M | $-106.36M | $-110.95M | $-78.21M | $-34.00M | $-414.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.47% | -4.57% | - | 3.42% | 0.68% | 1.12% | 1.26% | 1.03% | 0.89% | 1.04% | 2.35% | 0.62% |
Legend Biotech's average Quarter net income forecast for Mar 23 is $-76.23M, with a range of $-82.76M to $-70.72M. LEGN's average Quarter net income forecast represents a -123.83% decrease compared to the company's last Quarter net income of $319.93M (Dec 22).
Legend Biotech SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 6 | 10 | 10 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.16M | $-242.82M | - | $45.49M | $33.96M | $69.95M | $31.34M | $26.03M | $22.16M | $33.35M | $15.32M | $14.06M |
| Avg Forecast | $504.05M | $459.12M | $418.19M | $380.91M | $309.62M | $269.23M | $256.91M | $200.58M | $181.88M | $144.64M | $133.06M | $152.16M | $99.94M | $103.31M | $60.16M | $44.80M | $38.31M | $35.71M | $35.71M | $10.29M | $5.65M | $6.59M | $4.69M | $9.38M | $9.38M | $6.53M | $21.43M |
| High Forecast | $537.30M | $489.40M | $445.77M | $406.03M | $330.04M | $286.99M | $273.85M | $213.81M | $193.88M | $157.07M | $141.83M | $162.20M | $112.80M | $110.13M | $64.13M | $47.76M | $40.83M | $38.07M | $35.71M | $13.48M | $7.40M | $8.63M | $6.14M | $12.28M | $12.28M | $7.83M | $25.72M |
| Low Forecast | $476.05M | $433.62M | $394.96M | $359.75M | $292.42M | $254.28M | $242.64M | $189.44M | $171.78M | $131.59M | $125.67M | $143.71M | $86.63M | $97.57M | $56.82M | $42.31M | $36.18M | $33.73M | $35.71M | $6.53M | $3.59M | $4.18M | $2.98M | $5.95M | $5.95M | $5.22M | $17.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | -6.34% | - | 1.27% | 3.30% | 12.38% | 4.76% | 5.55% | 2.36% | 3.56% | 2.35% | 0.66% |
Legend Biotech's average Quarter SG&A projection for Jun 23 is $60.16M, based on 6 Wall Street analysts, with a range of $56.82M to $64.13M. The forecast indicates a 49.81% rise compared to LEGN last annual SG&A of $40.16M (Mar 23).
Legend Biotech EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 6 | 10 | 10 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.68 | $2.01 | - | $-1.25 | $-0.27 | $-0.58 | $-0.84 | $-0.66 | $-0.62 | $-0.44 | $-0.50 | $-1.98 |
| Avg Forecast | $0.43 | $0.36 | $0.25 | $0.15 | $-0.06 | $-0.13 | $-0.13 | $-0.22 | $-0.31 | $-0.34 | $-0.29 | $-0.19 | $-0.36 | $-0.31 | $-0.36 | $-0.42 | $-0.38 | $-0.31 | $-0.31 | $-0.34 | $-0.42 | $-0.34 | $-0.35 | $-0.28 | $-0.31 | $-0.26 | $-0.67 |
| High Forecast | $0.46 | $0.39 | $0.27 | $0.17 | $-0.05 | $-0.12 | $-0.12 | $-0.20 | $-0.28 | $-0.26 | $-0.27 | $-0.18 | $-0.21 | $-0.29 | $-0.33 | $-0.39 | $-0.36 | $-0.29 | $-0.31 | $-0.18 | $-0.22 | $-0.18 | $-0.18 | $-0.15 | $-0.16 | $-0.14 | $-0.53 |
| Low Forecast | $0.39 | $0.34 | $0.23 | $0.14 | $-0.06 | $-0.14 | $-0.14 | $-0.24 | $-0.33 | $-0.44 | $-0.31 | $-0.21 | $-0.44 | $-0.34 | $-0.39 | $-0.45 | $-0.42 | $-0.34 | $-0.31 | $-0.48 | $-0.58 | $-0.47 | $-0.49 | $-0.40 | $-0.43 | $-0.36 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.63% | -5.25% | - | 4.03% | 0.79% | 1.40% | 2.51% | 1.89% | 2.19% | 1.43% | 1.92% | 2.96% |
According to 3 Wall Street analysts, Legend Biotech's projected average Quarter EPS for Mar 23 is $-0.42, with a low estimate of $-0.45 and a high estimate of $-0.39. This represents a -120.77% decrease compared to LEGN previous annual EPS of $2.01 (Dec 22).
Legend Biotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZLAB | Zai Lab | $19.85 | $101.00 | 408.82% | Buy |
| PLRX | Pliant Therapeutics | $12.87 | $40.50 | 214.69% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| ETNB | 89bio | $8.47 | $22.00 | 159.74% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| TVTX | Travere Therapeutics | $10.98 | $19.50 | 77.60% | Buy |
| AKRO | Akero Therapeutics | $26.41 | $43.50 | 64.71% | Buy |
| LEGN | Legend Biotech | $48.29 | $78.78 | 63.14% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| ASND | Ascendis Pharma | $119.15 | $175.15 | 47.00% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $243.89 | $315.75 | 29.46% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| PCVX | Vaxcyte | $111.58 | $117.00 | 4.86% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.78 | $250.16 | 1.37% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
LEGN Forecast FAQ
Is Legend Biotech a good buy?
Yes, according to 12 Wall Street analysts, Legend Biotech (LEGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 91.67% of LEGN's total ratings.
What is LEGN's price target?
Legend Biotech (LEGN) average price target is $78.78 with a range of $60 to $90, implying a 63.14% from its last price of $48.29. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Legend Biotech stock go up soon?
According to Wall Street analysts' prediction for LEGN stock, the company can go up by 63.14% (from the last price of $48.29 to the average price target of $78.78), up by 86.37% based on the highest stock price target, and up by 24.25% based on the lowest stock price target.
Can Legend Biotech stock reach $70?
LEGN's average twelve months analyst stock price target of $78.78 supports the claim that Legend Biotech can reach $70 in the near future.
What are Legend Biotech's analysts' financial forecasts?
Legend Biotech's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $975.58M (high $1.04B, low $921.39M), average EBITDA is $-976M (high $-921M, low $-1.04B), average net income is $-97.875M (high $-90.806M, low $-106M), average SG&A $1.04B (high $1.1B, low $978.78M), and average EPS is $-0.536 (high $-0.497, low $-0.582). LEGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.66B (high $1.77B, low $1.57B), average EBITDA is $-1.659B (high $-1.567B, low $-1.768B), average net income is $217.1M (high $235.71M, low $201.42M), average SG&A $1.76B (high $1.88B, low $1.66B), and average EPS is $1.19 (high $1.29, low $1.1).
Did the LEGN's actual financial results beat the analysts' financial forecasts?
Based on Legend Biotech's last annual report (Dec 2022), the company's revenue was $117M, which missed the average analysts forecast of $117.57M by -0.48%. Apple's EBITDA was $-437M, beating the average prediction of $-115M by 279.95%. The company's net income was $-446M, beating the average estimation of $-245M by 82.03%. Apple's SG&A was $174.05M, beating the average forecast of $120.02M by 45.01%. Lastly, the company's EPS was $-2.81, beating the average prediction of $-1.345 by 108.87%. In terms of the last quarterly report (Mar 2023), Legend Biotech's revenue was $36.34M, missing the average analysts' forecast of $42.18M by -13.85%. The company's EBITDA was $-127M, beating the average prediction of $-42.177M by 200.78%. Legend Biotech's net income was $-112M, beating the average estimation of $-76.227M by 47.06%. The company's SG&A was $40.16M, missing the average forecast of $44.8M by -10.37%. Lastly, the company's EPS was $-0.68, beating the average prediction of $-0.417 by 62.89%